Prostate cancer is one of the most common cancers in men, but it is also one of the most treatable when discovered early. To lead the efforts of NYU Langone Hospital—Brooklyn in the early detection of prostate cancer and urinary cancer, Mohit Gupta, MD, has been appointed director of urologic oncology.
Dr. Gupta, a urologic oncologist, is highly trained in the use of advanced detection technology and minimally invasive robotic surgery. He recently completed the prestigious Warburton and Jewett Fellowship in Urologic Oncology at the Brady Urological Institute at Johns Hopkins Hospital in Baltimore, Maryland. As part of the fellowship, he underwent comprehensive two-year multidisciplinary training on the latest methods in diagnosing and managing urologic malignancies, including the safest, most effective surgical techniques.
Prostate cancer is the most common cancer among men, with more than 150,000 cases diagnosed per year in the United States. In Brooklyn, there are nearly 1,500 new prostate cancer diagnoses each year, and Dr. Gupta hopes to apply the latest scientific breakthroughs in caring for these patients.
“Prostate cancer is entirely treatable when the latest techniques in early detection are applied,” says Dr. Gupta. “The key is to visit the doctor regularly and have access to technologies such as multiparametric MRI and advanced three-dimensional imaging, which we are fortunate to have at NYU Langone.”
Dr. Gupta, who is proficient in laparoscopic and robotic-assisted techniques, can more easily target trouble spots on the prostate using state-of-the-art imaging devices such as the Artemis, which combines computerized ultrasound and diagnostic MRI imaging to pinpoint suspicious areas of the prostate. The da Vinci® Xi, the most advanced robotic surgical system available, delivers unmatched surgical effectiveness and safety, even for complex procedures.
Dr. Gupta is also highly trained in the detection and treatment of kidney cancer and bladder cancer. He is currently studying certain indicators of renal tumors that may show if a growth is benign or malignant. “There are certain biomarkers in the blood and urine that may indicate if a tumor is a cancer or not,” says Dr. Gupta. “We are trying to definitively identify those biomarkers to determine if surgery is required.”
“Dr. Gupta adds to the top-tier talent in Brooklyn and brings the most up-to-date knowledge in the fight against cancers throughout the renal system,” says Frederick A. Gulmi, MD, chief of urology at NYU Langone Hospital—Brooklyn.
Dr. Gupta received his medical degree from Thomas Jefferson University in Philadelphia and a dual bachelor’s degree in chemistry and political science from Emory University in Atlanta. He completed his urology residency at the University of Florida. He has co-authored more than 20 peer-reviewed studies in the areas of diagnostic and surgical urology, including in the use of robotic-assisted surgical techniques to treat prostate cancer. His research pursuits will continue in coordination with NYU School of Medicine and Perlmutter Cancer Center.